奥美沙坦酯氢氯噻嗪片治疗原发性高血压患者的临床有效性及安全性分析

Clinical effectiveness and safety of olmesartan medoxomil and hydrochlorothiazide tablets in the treatment of patients with essential hypertension

目的观察原发性高血压患者应用奥美沙坦酯氢氯噻嗪片治疗的效果及安全性。方法80例原发性高血压患者,依据用药方案不同分为对照组和观察组,每组40例。对照组患者应用氯沙坦钾片进行治疗,观察组患者应用奥美沙坦酯氢氯噻嗪片进行治疗。对比两组患者的舒张压(DBP)、收缩压(SBP)、临床疗效、血清超敏C反应蛋白(hs-CRP)、肝细胞生长因子(HGF)以及药物不良反应发生情况。结果治疗后,观察组的DBP(76.15±3.26)mm Hg(1 mm Hg=0.133 kPa)、SBP(131.26±8.16)mm Hg均低于对照组的(82.95±5.18)、(140.25±9.18)mm Hg,差异具有统计学意义(P<0.05)。观察组的治疗总有效率为95.00%,高于对照组的77.50%,差异具有统计学意义(P<0.05)。治疗后,观察组血清hs-CRP、HGF水平均低于对照组,差异具有统计学意义(P<0.05)。两组患者药物不良反应发生率对比,差异无统计学意义(χ^(2)=0.213,P=0.644>0.05)。结论原发性高血压患者应用奥美沙坦酯氢氯噻嗪片治疗可获得满意疗效,能够更好地控制血压水平,同时安全性良好,建议将该药物在原发性高血压患者中应用并推广。

Objective To observe the effect and safety of olmesartan medoxomil and hydrochlorothiazide tablets in the treatment of patients with essential hypertension. Methods A total of 80 patients with essential hypertension were divided into control group and observation group according to different medication regimens, with 40 cases in each group. The control group was treated with losartan potassium tablets, and the observation group was treated with olmesartan smedoxomil and hydrochlorothiazide tablets. The diastolic blood pressure(DBP), systolic blood pressure(SBP), clinical efficacy, serum high-sensitivity C-reactive protein(hs-CRP), hepatocyte growth factor(HGF) and occurrence of adverse drug reactions were compared between the two groups. Results After treatment, the DBP(76.15±3.26) mm Hg(1 mm Hg=0.133 kPa) and SBP(131.26±8.16) mm Hg of the observation group were all lower than(82.95±5.18) and(140.25±9.18) mm Hg of the control group, and the difference was statistically significant(P<0.05). The total effective rate of treatment of the observation group was 95.00%, which was higher than 77.50% of the control group, and the difference was statistically significant(P<0.05). After treatment, the serum hs-CRP and HGF of the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of adverse drug reactions between the two groups(χ2=0.213, P=0.644>0.05). Conclusion Olmesartan medoxomil and hydrochlorothiazide tablets show satisfactory efficacy on patients with essential hypertension, which can better control the blood pressure of patients with high safety. It is recommended to be applied and promoted in patients with essential hypertension.